<?xml version="1.0" encoding="UTF-8"?>
<p class="p">The susceptibility to ciprofloxacin, co-trimoxazole and MUP of 
 <italic class="italic">S. aureus</italic> isolates was assessed 
 <italic class="italic">via</italic> disc diffusion method and interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommendations. MRSA phenotype was determined using cefoxitin. The presence of macrolide-lincosamide-streptogramin B (MLS
 <sub class="sub">B</sub>) resistance phenotype was determined using erythromycin and clindamycin in accordance with Clinical and Laboratory Standards Institute (CLSI) recommendations [
 <xref rid="cit0014" ref-type="bibr" class="xref">14</xref>â€“
 <xref rid="cit0017" ref-type="bibr" class="xref">17</xref>]. Antibiotic discs were provided by Diag-Med, Poland.
</p>
